These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 15381130

  • 1. Promising phase I results against new HIV target.
    Whelan J.
    Drug Discov Today; 2004 Oct 01; 9(19):823. PubMed ID: 15381130
    [No Abstract] [Full Text] [Related]

  • 2. Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor.
    Temesgen Z, Feinberg JE.
    Curr Opin Investig Drugs; 2006 Aug 01; 7(8):759-65. PubMed ID: 16955688
    [Abstract] [Full Text] [Related]

  • 3. Determinants of activity of the HIV-1 maturation inhibitor PA-457.
    Li F, Zoumplis D, Matallana C, Kilgore NR, Reddick M, Yunus AS, Adamson CS, Salzwedel K, Martin DE, Allaway GP, Freed EO, Wild CT.
    Virology; 2006 Aug 01; 356(1-2):217-24. PubMed ID: 16930665
    [Abstract] [Full Text] [Related]

  • 4. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients.
    Malet I, Wirden M, Derache A, Simon A, Katlama C, Calvez V, Marcelin AG.
    AIDS; 2007 Apr 23; 21(7):871-3. PubMed ID: 17415044
    [Abstract] [Full Text] [Related]

  • 5. [The role of structural protein Gag and related gene (protein) in late stages of the HIV-1 replication cycle and the inhibitors].
    Jiang Y, Liu XY.
    Yao Xue Xue Bao; 2010 Feb 23; 45(2):205-14. PubMed ID: 21351430
    [Abstract] [Full Text] [Related]

  • 6. 3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro.
    Sakalian M, McMurtrey CP, Deeg FJ, Maloy CW, Li F, Wild CT, Salzwedel K.
    J Virol; 2006 Jun 23; 80(12):5716-22. PubMed ID: 16731910
    [Abstract] [Full Text] [Related]

  • 7. Viral drug resistance and fitness.
    Quiñones-Mateu ME, Moore-Dudley DM, Jegede O, Weber J, J Arts E.
    Adv Pharmacol; 2008 Jun 23; 56():257-96. PubMed ID: 18086415
    [No Abstract] [Full Text] [Related]

  • 8. Maturation inhibitors: a new therapeutic class targets the virus structure.
    Salzwedel K, Martin DE, Sakalian M.
    AIDS Rev; 2007 Jun 23; 9(3):162-72. PubMed ID: 17982941
    [Abstract] [Full Text] [Related]

  • 9. Molecule of the month. PA-457.
    Drug News Perspect; 2004 May 23; 17(4):283. PubMed ID: 15334176
    [No Abstract] [Full Text] [Related]

  • 10. The 3-O-(3',3'-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells.
    DaFonseca S, Blommaert A, Coric P, Hong SS, Bouaziz S, Boulanger P.
    Antivir Ther; 2007 May 23; 12(8):1185-203. PubMed ID: 18240859
    [Abstract] [Full Text] [Related]

  • 11. Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1.
    Zhao Y, Gu Q, Morris-Natschke SL, Chen CH, Lee KH.
    J Med Chem; 2016 Oct 13; 59(19):9262-9268. PubMed ID: 27676157
    [Abstract] [Full Text] [Related]

  • 12. Structure and anti-HIV activity of micrandilactones B and C, new nortriterpenoids possessing a unique skeleton from Schisandra micrantha.
    Li RT, Han QB, Zheng YT, Wang RR, Yang LM, Lu Y, Sang SQ, Zheng QT, Zhao QS, Sun HD.
    Chem Commun (Camb); 2005 Jun 21; (23):2936-8. PubMed ID: 15957031
    [Abstract] [Full Text] [Related]

  • 13. HIV type 1 integrase inhibitors: from basic research to clinical implications.
    Jegede O, Babu J, Di Santo R, McColl DJ, Weber J, Quiñones-Mateu M.
    AIDS Rev; 2008 Jun 21; 10(3):172-89. PubMed ID: 18820719
    [Abstract] [Full Text] [Related]

  • 14. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.
    Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO, Wild CT.
    Proc Natl Acad Sci U S A; 2003 Nov 11; 100(23):13555-60. PubMed ID: 14573704
    [Abstract] [Full Text] [Related]

  • 15. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
    Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE.
    Antimicrob Agents Chemother; 2007 Oct 11; 51(10):3574-81. PubMed ID: 17638699
    [Abstract] [Full Text] [Related]

  • 16. Maturation inhibitors as new antiretroviral agents.
    Richards J, McCallister S.
    J HIV Ther; 2008 Dec 11; 13(4):79-82. PubMed ID: 19418657
    [No Abstract] [Full Text] [Related]

  • 17. CCR5 inhibitors: promising yet challenging.
    Clotet B.
    J Infect Dis; 2007 Jul 15; 196(2):178-80. PubMed ID: 17570103
    [No Abstract] [Full Text] [Related]

  • 18. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
    Salgado M, Toro C, Simón A, Garrido C, Blanco F, Soriano V, Rodés B.
    J Clin Virol; 2009 Oct 15; 46(2):173-5. PubMed ID: 19625211
    [Abstract] [Full Text] [Related]

  • 19. A new assault on HIV.
    Stix G.
    Sci Am; 2006 Jun 15; 294(6):76-9. PubMed ID: 16711363
    [No Abstract] [Full Text] [Related]

  • 20. Cooperative contribution of gag substitutions to nelfinavir-dependent enhancement of precursor cleavage and replication of human immunodeficiency virus type-1.
    Matsuoka-Aizawa S, Gatanaga H, Sato H, Koike K, Kimura S, Oka S.
    Antiviral Res; 2006 Jun 15; 70(2):51-9. PubMed ID: 16487604
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.